Oculis Holding AG (OCS)
| Market Cap | 1.93B +103.9% |
| Revenue (ttm) | 1.51M +74.8% |
| Net Income | -124.80M |
| EPS | -2.39 |
| Shares Out | 59.17M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 484,933 |
| Open | 31.02 |
| Previous Close | 31.09 |
| Day's Range | 30.90 - 32.76 |
| 52-Week Range | 16.00 - 32.76 |
| Beta | 0.20 |
| Analysts | Strong Buy |
| Price Target | 42.00 (+28.68%) |
| Earnings Date | May 19, 2026 |
About OCS
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company’s lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological da... [Read more]
Financial Performance
In 2025, Oculis Holding AG's revenue was 1.20 million, an increase of 74.78% compared to the previous year's 686,000. Losses were -98.96 million, 15.4% more than in 2024.
Financial numbers in CHF Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for OCS stock is "Strong Buy." The 12-month stock price target is $42.0, which is an increase of 28.68% from the latest price.
News
Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial
ZUG, Switzerland, May 7 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical need...
Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting
Key findings from the DME AWARE initiative highlight the importance of non-invasive treatment options for early intervention in diabetic macular edema (DME) management Oculis is on track to report top...
Oculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
ZUG, Switzerland, May 01, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant u...
Oculis Publishes Invitation to the Annual General Meeting
ZUG, Switzerland, April 21, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis”), today published the invitation to the 2026 Annual General Meeting, which will be held on May...
Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema
ZUG, Switzerland, April 20, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant...
Oculis Holding AG Transcript: 25th Annual Needham Virtual Healthcare Conference
Three late-stage assets are advancing in large ophthalmic and neuro-ophthalmic markets, with OCS-01 phase III results expected in June, licaminlimab targeting a genotype-defined dry eye population, and privosegtor in registrational trials for rare optic neuropathies. Strong financials and regulatory support position the pipeline for multiple milestones through 2027.
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
ZUG, Switzerland, April 08, 2026 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to a director of the Company.
Oculis to Participate in Upcoming Investor Conferences
ZUG, Switzerland, April 07, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing ophtha...
Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic Neuritis
ZUG, Switzerland, March 31, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant...
Three new option listings on March 17th
New option listings for March 17th include GBank Financial Holdings Inc (GBFH), Oculis Holding AG (OCS), and Sionna Therapeutics Inc (SION).
Oculis to Present at Upcoming North American Neuro-Ophthalmology Society Annual Meeting
ZUG, Switzerland, 16 March, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical ne...
Oculis Holding AG Transcript: Leerink Global Healthcare Conference 2026
Three phase III programs are advancing, with a topical DME therapy nearing pivotal data and a biomarker-driven dry eye trial set for Q4 results. Neuroprotection candidate Privosegtor shows strong efficacy in optic neuritis, with premium pricing anticipated.
Oculis price target raised to $50 from $40 at Stifel
Stifel raised the firm’s price target on Oculis (OCS) to $50 from $40 and keeps a Buy rating on the shares after having hosted management on the road. The company
Oculis Publishes 2025 Consolidated Financial Statements
ZUG, Switzerland, March 05, 2026 (GLOBE NEWSWIRE) -- Following the Company‘s press release published on March 3, the audited consolidated financial statements for the financial year 2025 and the MD&A,...
Oculis files automatic mixed securities shelf
16:21 EST Oculis (OCS) files automatic mixed securities shelf
Oculis price target raised to $44 from $42 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Oculis (OCS) to $44 from $42 and keeps a Buy rating on the shares following the Q4 report. The firm believes OCS-01
Oculis reports Q4 EPS (CHF 0.42c) vs. (CHF 0.67) last year
Riad Sherif, CEO of Oculis (OCS), stated “Oculis has delivered a transformative 2025, marked by significant clinical progress across our late-stage portfolio and a strategic expansion into neuro-ophth...
Oculis Reports Q4 and Full Year 2025 Financial Results and Provides Company Update
Significant achievements in 2025, enabling multiple near-term clinical milestones across late-stage portfolio, starting with the forthcoming topline results from DIAMOND Phase 3 trials with OCS-01 eye...
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated
ZUG, Switzerland, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting of earnout shares and associated removal of restrictions on these ordinary shares.
Oculis Appoints Katie Kazem as Chief Legal Officer
ZUG, Switzerland, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significan...
Oculis Holding AG Transcript: 44th Annual J.P. Morgan Healthcare Conference
Three late-stage assets are advancing: OCS-01 for DME expects phase III results in Q2 and targets 2027 approval; Licaminlimab targets dry eye with a precision approach and 2026 readout; Privosegtor leads in neuroprotection with phase III trials and breakthrough status. Rapid adoption and large market opportunities are expected, backed by strong execution and financial stability.
Oculis to Showcase Transformative Late-stage Pipeline in Neuro-ophthalmology and Ophthalmology at the 2026 J.P. Morgan Healthcare Conference
ZUG, Switzerland, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significan...
Oculis up 9% after announcing breakthrough therapy designation for Privosegtor
Oculis (OCS) Holding announced that its neuroprotective candidate Privosegtor was granted breakthrough therapy designation by the U.S. Food and Drug Administration for treatment of optic neuritis. The...
Oculis Announces U.S. FDA Breakthrough Therapy Designation Granted to Privosegtor for Treatment of Optic Neuritis
ZUG, Switzerland, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Breakthrough Therapy Designation granted to Privosegtor, a neuroprotective candidate, for the treatment of optic neuritis Privosegtor is advancing i...
Oculis price target raised to $40 from $35 at Stifel
Stifel analyst Annabel Samimy raised the firm’s price target on Oculis (OCS) to $40 from $35 and keeps a Buy rating on the shares as part of a 2026 outlook